Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition

Author： Coyne C. P.   Ross Matt   Bailey John  

Publisher： Informa Healthcare

ISSN： 1061-186X

Source： Journal of Drug Targeting, Vol.17, Iss.6, 2009-07, pp. : 474-489

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-HER2 Cancer Therapy and Cardiotoxicity

By  

Current Pharmaceutical Design, Vol. 20, Iss. 30, 2014-09 ,pp. : 4911-4919

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting P-glycoprotein for Effective Oral Anti-Cancer Chemotherapeutics

By  

Current Cancer Drug Targets, Vol. 8, Iss. 1, 2008-02 ,pp. : 47-52

Bentham Science Publishers

Access to resources Recommend Favorite

The HER2 CISH pharmDx ™ Kit in the assessment of breast cancer patients for anti-HER2 treatment

By Foged Niels T   Brügmann Anja   Jørgensen Jan T  

Expert Review of Molecular Diagnostics, Vol. 13, Iss. 3, 2013-04 ,pp. : 233-242

Informa Healthcare

Access to resources Recommend Favorite

Inhibition of P-glycoprotein in tumour cells

By LeBlanc G.A.  

Expert Opinion on Therapeutic Targets, Vol. 2, Iss. 1, 1998-07 ,pp. : 121-123

Informa Healthcare

Access to resources Recommend Favorite

Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma

By  

Current Cancer Drug Targets, Vol. 9, Iss. 8, 2009-12 ,pp. : 931-937

Bentham Science Publishers

Access to resources Recommend Favorite